Amgen has discontinued development of its early-stage obesity drug AMG 513, moving forward with phase 3 candidate MariTide (also known as maridebart cafraglutide or AMG 133) as its primary obesity asset.
The decision to halt AMG 513 follows a prior discontinuation of another early obesity candidate, AMG 786, underscoring a strategic refocusing on MariTide.
MariTide is a bispecific antibody–peptide conjugate targeting GLP-1 and inhibiting GIP receptors, designed for infrequent dosing (potentially four to six times per year), and is now in phase 3 trials for obesity, type 2 diabetes, and related cardiometabolic conditions.
Recent phase 2 data for MariTide showed double‑digit average body‑weight reductions over 52 weeks, with manageable gastrointestinal side effects, boosting investor and analyst interest ahead of phase 3 readouts.
Sources:
Amgen drops early-stage obesity drug, upping pressure on ...
Amgen 'encouraged' by weight-loss drug interim data, ...
Study of Amgen's early obesity candidate paused by FDA
Amgen Advances Obesity Pipeline With Fresh Data on ...
Amgen second-quarter sales rise 9%, profit tops Street view
Amgen Lifts Outlook on Strong 2Q Drug Sales, to End Early ...
Pipeline Problems Mar Amgen's Q4 Beat - BioSpace
Amgen drops obesity drug after phase 1 results, focuses on ...
Amgen announces hold on Phase 1 obesity candidate, ...
Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug
Amgen Eyes 2026 'Springboard' as Growth Drugs Offset ...
Amgen's early-stage obesity asset slapped with FDA hold
Three Drugmakers Advance Obesity Pipelines with New Mechanisms and Clinical Plans | MedTrace
Amgen updates phase 2 obesity data, shares closely watched by ...